

**Investment Objective**

The investment objective of the Kieger UCITS Fund - Kieger Impact Healthcare Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals. The fund is actively managed by the Investment Manager.

**SFDR classification: Article 9**

The fund has sustainable investment as its objective.

**Key Information**

**General Information**

ISIN	LU2488093530
BLOOMBERG	KGIHAAC LX
Fund Inception	01/10/2020
Share Class Inception	20/03/2023
Total Assets	USD 86.5m
Fund Currency	USD
Domicile	Luxembourg
Regulatory Status	SICAV
Legal Structure	UCITS
Dealing Frequency	Daily (CET 12pm)
Settlement	T+2
Distribution Policy	Accumulating

**Service Providers**

Management Company	FundRock Management Co. SA
Investment Manager	Kieger AG
Custodian Bank/ Administrator	Northern Trust Global Services SE
Auditor	Ernst & Young SA

**Fund Management**

Maria Specogna (Co-Mgr)
Raphael Oesch (Co-Mgr)

**Portfolio Statistics (3-Year Annualised)**

	Fund
Volatility	22.25%
Sharpe Ratio	-0.42
Tracking Error	-
Information Ratio	-
Beta	1.36
Active Share	89.15%

**Largest Holdings (%)**

Intra-Cellular Therapies Inc	4.8%
Hikma Pharmaceuticals PLC	3.9%
Ambu A/S	3.9%
DexCom Inc	3.7%
Abbott Laboratories	3.7%
Sandoz Group AG	3.6%
Penumbra Inc	3.6%
Amplifon Spa	3.6%
Revvity Inc	3.5%
Demant A/S	3.5%
<b>Total Top 10 - out of 33</b>	<b>37.8%</b>


**Performance (%)**

Performance data are net of management fees, but do not reflect sales charges or the effect of taxes.



Past performance is no indication of current or future performance.

	1 Month	3 Months	YTD	1 Yr	3 Yrs	5 Yrs
CHF B Class Accumulating	10.72%	13.69%	10.72%	9.08%	-	-



Past performance is no indication of current or future performance.

**Manager Commentary**

**Market review:** January was an eventful start to the year for healthcare. First, companies gave a 360° overview of key topics at the JP Morgan healthcare conference, with many pre-announcing full-year results or giving 2025 guidance. Second, the Trump inauguration and RFK confirmation hearings provided some reassurance regarding the future policy landscape, though headline risk remains high. Third, the kick-off of Q4 reporting confirmed the trend seen at the conference, namely that the sector continues to benefit from rising utilization rates driven by the aging population. This demographic trend is expected to sustain robust sales growth. Medtech companies have specifically pointed out that this is not pent-up demand, but the "new normal". Demand for therapeutics is strong, in particular in areas where age is a major risk factor, such as oncology and chronic autoimmune diseases. Overall, we see aligned fundamentals and sentiment providing a strong backdrop for 2025 in healthcare.


**Portfolio changes:** We did not initiate a new position and no position was exited.

**Performance review:** The largest contributors were Intra-Cellular (+182 bps / J&J; aims to acquire Intra-Cellular for a total equity value of USD 14.6bn), Ambu (+100 bps / Reported preliminary fiscal Q1 revenue above consensus and the full year guidance was raised. Ambu showed continued strong growth in both pulmonology and urology, ENT and GI within Endoscopy Solutions. Anaesthesia & Patient Monitoring was positive, too) and Axsome (+68 bps / Releases preliminary results, which were in-line with consensus and Auvelity prescriptions continuing to do well). The largest detractors were RadNet (-20 bps / Momentum from December continued into January (profit taking following a 101% return in 2025). Later, various brokers adjusted 2025 EBITDA estimates, driven by management pointing to 1) planned new sales-and infrastructure investments to support expected growth in their Digital Health unit and 2) higher than average wage inflation), New Amsterdam (-17 bps / No news since strong positive phase 3 Broadway data mid-December) and Novo Nordisk (-8 bps / Obesity-related firms sold-off after Eli Lilly preannounced Q4 revenues below consensus. Later, CMS published the next 15 drugs for Medicare price negotiations (including Ozempic, Wegovy, Rybelsus). Novo Nordisk recouped some of the losses after announcing topline results from a phase 1B/2a trial with amycretin in people with overweight/obesity).


**ESG:** Firms in the portfolio did not report any material ESG issues in January.

as of 31/01/2025


**Regional Exposure (%)**



**Sector Exposure (%)**




**Market Cap Breakdown (%)**



Large = >15bn, Mid = 5-15bn, Small = <5bn

**Impact Theme Allocation (%)**



**Share Class Information**

Share Class	ISIN	Bloomberg	Investment Management Fee	TER - as of Dec 2023	Minimum Investment	NAV
USD A Class Accumulating	LU2207278073	KGIHAUA LX	1.00%	1.21%	500,000	86.66
CHF A (H) Class Acc	LU2207278404	KGIHAHC LX	1.00%	1.27%	500,000	88.17
USD B Class Accumulating	LU2488093613	KGIHAUA LX	1.00%	1.22%	5,000	99.09
EUR B Class Accumulating	LU2488093456	KGIHAAE LX	1.00%	1.22%	5,000	101.8
CHF B Class Accumulating	LU2488093530	KGIHAAC LX	1.00%	1.22%	5,000	97.89
USD R Class Accumulating	LU2207278669	KGIHRUA LX	2.00%	2.22%	2,000	95.79

**Disclaimer**

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus.

A summary of the investor rights is available in English at

<https://kieger.com/regulatory-disclosures> Further information about the sustainability-related aspects of the Fund is available at

<https://kieger.com/regulatory-disclosures>. The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

**Information for Swiss Investors:**

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Maintower, Thurgauerstrasse 36/38, CH-8050 Zurich, Switzerland, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

**Information for German Investors:**

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Line-Eid-Strasse 6, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email [facilityagent@acolin.com](mailto:facilityagent@acolin.com), or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

**Information for Austrian Investors:** The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email [foreignfunds0540@erstebank.at](mailto:foreignfunds0540@erstebank.at)

**Marketing in the European Union:**

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II" as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his home country Luxembourg. Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be copied or used for other purposes, nor may the content of the document be forwarded to third parties.